Please check your internet connection and try again.
# Aztreonam-avibactam (Emblaveo)
## Overview
Aztreonam-avibactam is a fixed-dose combination of a monobactam antibiotic (aztreonam) and a diazabicyclooctane beta-lactamase inhibitor (avibactam). It is specifically engineered to overcome resistance caused by metallo-beta-lactamases (MBLs), such as NDM-1, which hydrolyze most other beta-lactams. *Note: As of mid-2024, branding and availability may vary globally (e.g., marketed as Emblaveo in the EU; not currently FDA-approved).*
## Primary Indications
Treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI/pyelonephritis), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) caused by aerobic Gram-negative organisms, including those producing MBLs.
## Adult Dosing
The standard regimen is 2 grams of aztreonam and 0.5 grams of avibactam (total 2.5g) administered via intravenous infusion over 2 hours, every 8 hours.
## Pediatric Dosing
Limited data exist. Dosing generally follows weight-based regimens similar to aztreonam monotherapy adjusted for the avibactam component. Pediatric dosing should strictly follow institution-specific protocols or the EMA/local regulatory-approved summary of product characteristics as evidence is evolving.
## Dose Adjustments
* **Renal Impairment:** Requires significant dose reduction based on CrCl. For CrCl < 60 mL/min, the interval and/or dose must be adjusted. Consult specific titration tables (e.g., EMA prescribing information) as this is highly sensitive to renal function.
* **Hepatic Impairment:** No dose adjustment typically required.
## Contraindications
Hypersensitivity to aztreonam, avibactam, or any component of the formulation. History of severe hypersensitivity (e.g., anaphylaxis, DRESS syndrome) to any other beta-lactam antibiotic.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, increased liver transaminases (ALT/AST).
* **Serious:** Clostridioides difficile-associated diarrhea (CDAD), hypersensitivity reactions, seizures (rare, primarily in renal impairment).
## Key Drug Interactions
* **Probenecid:** Inhibits renal tubular secretion of aztreonam, potentially increasing systemic exposure.
* **Other Antibiotics:** Generally compatible, but monitor for additive nephrotoxicity if used with aminoglycosides or vancomycin.
## Monitoring
* **Renal Function:** Monitor serum creatinine and adjust dosage as necessary.
* **Liver Function:** Baseline and periodic monitoring of transaminases if prolonged therapy is required.
* **Clinical Response:** Monitor for signs of therapeutic improvement or new-onset diarrhea/superinfection.
## Clinical Pearls
* **Spectrum:** It is highly active against Gram-negative Enterobacterales, including those producing MBLs (e.g., NDM) and ESBLs/KPC. It has no activity against Gram-positive bacteria or anaerobes.
* **Administration:** Must be administered as a prolonged infusion (2 hours) to optimize pharmacodynamic target attainment.
* **Availability:** Prescribing necessitates confirmation of local regulatory approval and site-specific infectious disease committee endorsement. Ensure the "Avycaz" branding is not confused with Ceftazidime-avibactam (which also uses the Avycaz trade name in the US).
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical guidelines and prescribing information (including FDA/EMA labels) are subject to change. Always verify current prescribing information, institutional formulary status, and patient-specific contraindications via official drug monographs and clinical pharmacology resources before prescribing.
